Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
78 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 52.72 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 78.93 | Oscillator | Neutral |
| Williams %R (14) | -33.33 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.09 (Hist 0.01) | Oscillator | Strong Buy |
| Average Directional Index (14) | 27.55 (+DI 21.1 / -DI 10.7) | Trend | Strong Buy |
Current price $6.71
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 14, 26 | Needham |
| EMA 20 | 6.61 | MA | Buy |
| SMA 20 | 6.56 | MA | Buy |
| EMA 50 | 6.37 | MA | Strong Buy |
| SMA 50 | 6.46 | MA | Strong Buy |
| SMA 200 | — | MA | Neutral |
| Buy |
| Buy |
| Jul 9, 26 | BTIG | maintain | Buy | Buy |
| Jun 17, 26 | Needham | maintain | Buy | Buy |
| Jun 8, 26 | BTIG | maintain | Buy | Buy |
| Mar 13, 26 | B. Riley Securities | maintain | Buy | Buy |
| Mar 13, 26 | Needham | maintain | Buy | Buy |
| Mar 9, 26 | Needham | maintain | Buy | Buy |
| Mar 9, 26 | BTIG | maintain | Buy | Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 21, 26 | Hively Brad | director | S-Sale | 298,853 @ $6.51 | $1.95M |
| Aug 14, 26 | Chernett Jorey | 10 percent owner | P-Purchase | 12,000 @ $6.54 | $78.48K |
| Aug 13, 26 | Chernett Jorey | 10 percent owner | S-Sale | 100 @ $9.00 | $900 |
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | STLN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -22.4x | -10.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -41.3x | EPS est. -0.16 | Elevated |
| Price / Book | -27.7x | -34.1x | Discount |
| Price / Sales | 1.1x | 1.1x | In line |
| EV / EBITDA | -33.6x | -14.3x | Elevated |
| Return on equity | 209.8% | — | Top tier |
| Gross margin | 15.7% | 15.2% | In line |
| Debt / Equity | -4.19 | -6.60 | Conservative |
| Piotroski / Altman Z | —/9 | Z — | n/a |
Discounted cash flow model
Stock news · updated daily
Shares of Oncology Institute, Inc. (NASDAQ: STLN - Get Free Report) were up 6.1% on Friday. The stock traded as high as $6.56 and last traded at $6.56. Approximately 133,504 shares changed hands during trading, a decline of 92% from the average session volume of 1,771,716 shares. The stock had previously closed at $6.18. Analysts Set
During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums
Starling Oncology is rated BUY, supported by strong secular growth and expanding adoption of its oncology managed care services. STLN's revenue model leverages scalable delegation contracts, driving higher PMPM fees, pharmacy growth, and gross profit expansion. FY26 guidance was raised: revenue is up 31%, gross profit is up 41%, and positive EBITDA ($2–$7M) and free cash flow ($10M) are expected.
CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Wells Fargo Healthcare Conference, being held in Boston on Tuesday, September 8, 2026, including a fireside chat from 4:30–5:05 p.m.
CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer care's persistent challenges: NCCN compliance by the medical community and a fragmented and administratively burdensome prior authorization process for providers.
Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
The Oncology Institute, Inc. (STLN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.06 | -0.08 | Miss -25.0% | $161.3M |
| May 7, 2026 | -0.09 | -0.02 | Beat 77.1% | $147.4M |
| Aug 13, 2025 | -0.12 | -0.15 | Miss -25.0% | $119.8M |
| May 14, 2025 | — | -0.21 | — | $104.4M |
| Aug 13, 2024 | -0.09 | -0.17 | Miss -88.9% | $98.60M |